An experimental drug for the treatment of hepatitis C, miravirsen, is able to transfer hepatitis from the list of fatal to chronic. This is evidenced by the results of clinical trials..

Testing has shown that miravirsen suppresses the ability of the hepatitis C virus to reproduce. As a result, at the highest dose of the drug, the viral load is reduced by 500 times.. No drug resistance found.

The development of a new drug for the treatment of hepatitis C was led by Harry Janssen of the University of Toronto and Erasmus University.

The experiment involved 36 patients who took miravirsen for 29 days (dosage 3.5 mg or 7 mg per 1 kg of body weight, or placebo). An 18-week follow-up showed that in 4 out of 9 volunteers, taking the drug led to a decrease in the level of the virus below the detectable indicators..

About 170 million suffer from hepatitis C in the world. Human. Recall that in Ukraine, about 1.5 million are infected with the hepatitis C virus. Human.

aspekty. net.